Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jun;39(6):1240–1242. doi: 10.1128/aac.39.6.1240

Cefixime penetration in human renal parenchyma.

A Leroy 1, B Oser 1, P Grise 1, G Humbert 1
PMCID: PMC162719  PMID: 7574508

Abstract

The diffusion of cefixime, a new orally active expanded-spectrum cephalosporin, was studied in 12 patients undergoing nephrectomy after receiving 200-mg oral doses every 12 h for 2 days. The patients were divided into two groups according to the time of perioperative sampling after the last dose: 4 h (group 1) and 12 h (group 2). Preoperative blood samples were taken just before administration of the last dose of cefixime. Simultaneous blood and tissue samples were collected perioperatively at 4 h (time to peak level) and 12 h (residual level). The intrarenal concentrations of cefixime were measured by an isocratic reversed-phase high-pressure liquid chromatographic (HPLC) assay. Concentrations in serum were determined by both microbiological and HPLC assays. The mean peak levels in serum were 3.41 +/- 0.43 micrograms/ml (group 1), and the residual levels averaged 1.54 +/- 1.17 micrograms/ml (group 2). The diffusion in renal parenchyma was not significantly different in the cortexes and medullas of both groups of patients: 5.7 to 6.4 micrograms/g in group 1 and 4.6 to 4.7 micrograms/g in group 2. The decrease in cefixime concentrations was slower in tissue than in serum; the ratios of concentrations in tissue to those in serum were 3.5 to 3.6 and 1.7 to 1.9 at 4 and 12 h, respectively. The intrarenal concentrations of cefixime remained higher than the MIC for the most susceptible gram-negative bacteria during the time interval between the administration of two doses.

Full Text

The Full Text of this article is available as a PDF (193.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates. Pediatr Infect Dis J. 1987 Oct;6(10):954–957. [PubMed] [Google Scholar]
  2. Brittain D. C., Scully B. E., Hirose T., Neu H. C. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther. 1985 Nov;38(5):590–594. doi: 10.1038/clpt.1985.229. [DOI] [PubMed] [Google Scholar]
  3. Counts G. W., Baugher L. K., Ulness B. K., Hamilton D. J. Comparative in vitro activity of the new oral cephalosporin cefixime. Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):428–431. doi: 10.1007/BF01962357. [DOI] [PubMed] [Google Scholar]
  4. Cox C. E. Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections. Urology. 1989 Nov;34(5):322–326. doi: 10.1016/0090-4295(89)90335-x. [DOI] [PubMed] [Google Scholar]
  5. Debbia E. A., Marchese A., Pesce A., Saverino D., Schito G. C. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens. J Chemother. 1992 Jun;4(3):131–144. doi: 10.1080/1120009x.1992.11739153. [DOI] [PubMed] [Google Scholar]
  6. Dhib M., Moulin B., Leroy A., Hameau B., Godin M., Johannides R., Fillastre J. P. Relationship between renal function and disposition of oral cefixime. Eur J Clin Pharmacol. 1991;41(6):579–583. doi: 10.1007/BF00314988. [DOI] [PubMed] [Google Scholar]
  7. Falkowski A. J., Look Z. M., Noguchi H., Silber B. M. Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Nov 27;422:145–152. doi: 10.1016/0378-4347(87)80447-4. [DOI] [PubMed] [Google Scholar]
  8. Faulkner R. D., Bohaychuk W., Lanc R. A., Haynes J. D., Desjardins R. E., Yacobi A., Silber B. M. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 1988 Jun;21(6):787–794. doi: 10.1093/jac/21.6.787. [DOI] [PubMed] [Google Scholar]
  9. Freney J., Mongin-Long D., Meugnier H., Nervi C., Laville M., Zech P., Fleurette J. Etude de la diffusion de la ceftriaxone dans le parenchyme rénal. Pathol Biol (Paris) 1987 Jun;35(5 Pt 2):727–729. [PubMed] [Google Scholar]
  10. Guay D. R., Meatherall R. C., Harding G. K., Brown G. R. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 1986 Sep;30(3):485–490. doi: 10.1128/aac.30.3.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Montay G., Le Liboux A., Thebault J. J., Roche G., Frydman A., Gaillot J. Pharmacocinétique du céfixime chez le volontaire sain après administration orale unique à la dose de 200 mg. Presse Med. 1989 Oct 11;18(32):1583–1586. [PubMed] [Google Scholar]
  12. Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Powell M., Williams J. D. In vitro susceptibility of Haemophilus influenzae to cefixime. Antimicrob Agents Chemother. 1987 Nov;31(11):1841–1842. doi: 10.1128/aac.31.11.1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roncoroni A. J., Manuel C., Nedjar C., Bauchet J., Mariani D. Cefamandole bone diffusion in patients undergoing total hip replacement. Chemotherapy. 1981;27(3):166–172. doi: 10.1159/000237973. [DOI] [PubMed] [Google Scholar]
  15. Saito I., Saiko Y., Yokozawa M., Ono K., Tahara T., Hosoi Y. [A basic study on cefpirome]. Hinyokika Kiyo. 1991 Apr;37(4):441–446. [PubMed] [Google Scholar]
  16. Stone J. W., Linong G., Andrews J. M., Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221–228. doi: 10.1093/jac/23.2.221. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES